Lilly’s Taltz meets Phase IV trial’s primary endpoint in patients with moderate to severe plaque psoriasis. Credit: Momoneymoproblemz.

Eli Lilly has reported positive results from the head-to-head Phase IV IXORA-R clinical trial, where the company’s Taltz (ixekizumab) demonstrated superiority over Janssen’s Tremfya in plaque psoriasis.

Taltz is an IL-17A inhibitor, while Tremfya blocks IL-23/p19. The IXORA-R study compared the safety and efficacy of the drugs in 1,027 patients with moderate to severe plaque psoriasis.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The trial’s primary endpoint was the proportion of patients with Psoriasis Area Severity Index (PASI) 100 response at week 12.

The endpoint was met, with 41.3% of participants treated with Taltz experiencing complete skin clearance (PASI 100) at week 12 compared to 24.9% of those on Tremfya.

Lilly added that its drug also met all major secondary endpoints.

The trial’s major secondary endpoints include the proportion of patients with PASI 100 at weeks 4, 8 and 24, PASI 90 at weeks 4 and 8, PASI 75 at week 2, PASI 50 at week 1, as well as static Physician’s Global Assessment (sPGA) 0 at week 12.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Lilly immunology global brand development leader Rhonda Pacheco said: “As new medicines become available for people living with psoriasis, there’s an increasing need to directly compare the efficacy and safety of these treatments to help healthcare providers and patients make informed treatment decisions.

“These results demonstrate that Taltz can provide high levels of skin clearance early in treatment for people with psoriasis.”

Results further showed that the safety profiles of both the drugs were consistent with their previous data. The Phase IV IXORA-R trial is ongoing.

The data on the remaining key secondary endpoint of the proportion of patients with PASI 100 at week 24 is expected to be reported next year.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
YPrime won the Innovation award for AI in Clinical Trials and the Environmental award for Sustainable Trials, thanks to its eCOA, IRT and eConsent platforms. Explore how purpose-built AI, paperless workflows and circular hardware practices are reshaping timelines, data quality and ESG performance in clinical research.

Discover the Impact